Crucell Terug naar discussie overzicht

International Convention

1. [verwijderd] 27 april 2005 12:38

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Bio 2005
   Philadelphia
   Annual International Convention
   June 19-22, 2005.
   
   Innovative Immunotherapeutics
   Track: vaccines
   11.00 AM - 12.15 PM
   Room Number: 109 A/B
   
   Developments in vaccine technology over the past decade have transformed this market sector into a technology-driven industry.
   Prophylactic vaccines have been the main scope of this market. Although dramatic innovations in these preventive products are not expected, the category has become a hot topic again, due to biosafety and homeland security activities, as well as growing concern regarding pandemic threats as SARS and flu.
   A TIDAL WAVE OF GROWTH IS EXPECTED with the introduction of therapeutic vaccines to treat AIDS, cancer and other major diseases.
   DNA and protein-based therapeutic vaccines that boost the immune response to cancerous cells will add a powerfull new component to standard treatment for cancer.
   
   Chair
   Rob Meloen, Professor, Academic Biomedical Center, University of Utrecht.
   
   Speakers
   John Schiller, Senior Investigator, National Cancer Institute, National Institutes of Health
   
   Joost van Bree, CEO, Pepscan Systems
   
   Kristian Dalsgaard, CSO, Nordic Vaccine Technology A/S and University of Copenhagen
   
   Jaap Goudsmit, CSO, Crucell NV
   
   Biotechs and Not-For-Profits: Winning the mating game.
   
   Track: Global Health
   2:15 - 3:45 PM
   Room Number: 108 B
   
   This session will examine collaborations between not-for-profit product developers and industry to create public-private partnerships that address critical health issues facing the developing world.
   For biotechnology and pharmaceutical companies, partnering with a not-for-profit can help with clinical, regulatory, policy and advocacy needs. Not-for-profits can benefit significantly from scientific expertise and resources of industry.
   In the last five years, more than US$ 2 billion has been pledged to new not-for-profit ventures, and approximately 20 public-private partnerships now exist. Some have more than six years of experience and together, public-private partnerships have more than 25 products in development.
   This session will include industry and representatives of not-for-profit product developers discussing the advantages of working together while identifying the challenge to making such relationships effective.
   The panel will discuss how both groups can make themselves better partners and approach developing arrangements on specific issues, including royalty and patent agreements.
   
   Chair
   Kalpana Gupta, Director, Global Alliances and Initiatives, International AIDS Vaccine Initiative
   
   Speakers
   Joseph Bruder, Director, Vector and Vaccine Programs, Genvec Inc.
   
   Jaap Goudsmit, CSO, Crucell NV
   
   Polly Harrison, Director, Global Alliance for Microbicide Development
   
   Wendy Taylor, Executive Director, Bioventures for Global Health
   
   www.bio.org/events/2005/speakers/sess...
   
   www.bio.org/events/2005/
2. [verwijderd] 27 april 2005 12:41

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   de link doet het niet. mvg
3. [verwijderd] 7 juni 2005 13:14

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Holland Biodelta.
   
   Life sciences flourish where science, business and government unite.
   
   With more than 400 companies already active in life science, the Netherlands Hollandbiodelta is among Europe's largest life science markets.
   And the Dutch cluster continues to expand.
   
   The Netherlands focuses in particular on biomedical research, industrial biotech and food sciences.
   The strong knowledge base in these fields, combined with availability of funding, business accommodation and laboratory space, supporting services, and qualified personnel make the Netherlands an excellent place for start-ups as well as foreign companies looking for an European location.
   The Dutch succes in life sciences shows what can happen when government, business and science together focus on same goals.
   www.bio.org/events/2005/international
   
   Bio 2005, Philadelphia Annual International Convention, june 19-22-2005..................nog 12 dagen, dan komen we al aardig dicht bij een Brussiaanse zomer lijkt me.
   gr.
4. [verwijderd] 19 juni 2005 09:36

   auteur info

   • [verwijderd]

     Lid sinds: 01 jan 0001

     Laatste bezoek: 01 jan 0001

   • Aanbevelingen

     Ontvangen: 0

     Gegeven: 0

   •    Aantal posts: 0

   Innovation will be the key medical and scientific theme at the BIO 2005 Annual International Convention as researchers from around the world discuss new ways to predict, treat and someday cure some of man's most intractable diseases.
   
   More than 18,000 biotech executives, investors, journalists, policymakers and scientists from more than 60 countries are expected to attend.
   
   www.bio.org/events/2005/media/aboutBI...
   
   
5. Mr Greenspan 19 juni 2005 23:36

   auteur info

   • Mr Greenspan

     Lid sinds: 22 nov 2000

     Laatste bezoek: 30 mei 2024

   • Aanbevelingen

     Ontvangen: 2026

     Gegeven: 1864

   •    Aantal posts: 8.799

   Super toll! Dat wordt dus weer erg veel publiciteit, met de nodige belangstelling voor Crucell. THANKS.